De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis.

被引：0

作者：

Goldvaser, Hadar

Yasmin, Korzets Ceder

Shepshelovich, Daniel

Yerushalmi, Rinat

Sarfaty, Michal

Ribnikar, Domen

Thavendiranathan, Paaladinesh

Amir, Eitan

机构：

[1] Beilinson Med Ctr, Davidoff Ctr, Rabin Med Ctr, Kyriat Ono, Israel

[2] Beilinson Hosp 32393 Shem, Petah Tiqwa, Israel

[3] Rabin Med Ctr, Petah Tiqwa, Israel

[4] Rabin Med Ctr, Davidoff Canc Ctr, Petah Tiqwa, Israel

[5] Davidoff Canc Ctr, Petah Tiqwa, Israel

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Toronto Gen Hosp, Res Inst, Toronto, ON, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

10.1200/JCO.2019.37.15_suppl.524

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

524

引用

页数：1

共 50 条

[21] The impact of Human Epidermal growth factor Receptor 2 (HER2) expression by RT-PCR on tumor characteristics and outcome in estrogen receptor (ER) positive, HER2 negative early-stage breast cancer
Goldvaser, Hadar
Mutai, Raz
Stemmer, Salomon
Kuchuk, Iryna
Tokar, Margarita
Paluch-Shimon, Shani
Yerushalmi, Rinat
Drumea, Karen
Evron, Ella
Sonnenblick, Amir
Gal-Yam, Einav
Bar Sela, Gil
Shai, Ayelet
Merose, Rotem
Bareket-Samish, Avital
Soussan-Gutman, Lior
CANCER RESEARCH, 2024, 84 (09)
[22] De-escalating therapy dilemma in small HER2 positive node negative breast cancer
Hajjaji, Nawale
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] Adjuvant trastuzumab and vinorelbine for early-stage HER2+breast cancer
McLaughlin, Shannon
Nakajima, Erika
Bar, Yael
Hutchinson, Jennifer A. A.
Shin, Jennifer
Moy, Beverly
Isakoff, Steven J. J.
Bardia, Aditya
Kuter, Irene
Spring, Laura M. M.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[24] Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials
O'Sullivan, Ciara C.
Bradbury, Ian
Campbell, Christine
Spielmann, Marc
Perez, Edith A.
Joensuu, Heikki
Costantino, Joseph P.
Delaloge, Suzette
Rastogi, Priya
Zardavas, Dimitrios
Ballman, Karla V.
Holmes, Eileen
de Azambuja, Evandro
Piccart-Gebhart, Martine
Zujewski, Jo Anne
Gelber, Richard D.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (24) : 2600 - U37
[25] Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
Liberato, Nicola Lucio
Marchetti, Monia
Barosi, Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (06) : 625 - 633
[26] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
Yu, Ke-Da
Wang, Xin
Chen, Wan-Kun
Fan, Lei
Mo, Miao
Chen, Han
NPJ PRECISION ONCOLOGY, 2020, 4 (01)
[27] Tailored duration of adjuvant trastuzumab for human epidermal growth factor receptor 2-positive breast cancer
Ke-Da Yu
Xin Wang
Wan-Kun Chen
Lei Fan
Miao Mo
Han Chen
npj Precision Oncology, 4
[28] Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network
Freedman, Rachel A.
Hughes, Melissa E.
Ottesen, Rebecca A.
Weeks, Jane C.
He, Yulei
Wong, Yu-Ning
Theriault, Richard
Keating, Nancy L.
CANCER, 2013, 119 (04) : 839 - 846
[29] Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review
Mathew, Jacob
Perez, Edith A.
CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 594 - 600
[30] NON-INTERVENTIONAL, REAL-WORLD STUDY OF PATIENTS WITH EARLY STAGE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE BREAST CANCER RECEIVING BIOSIMILAR TRASTUZUMAB
Shelbaya, A.
Kale, H.
Poorman, G.
Inguva, S.
Alvir, J. M.
Bair, A.
Stephens, J. M.
VALUE IN HEALTH, 2022, 25 (07) : S489 - S489

← 1 2 3 4 5 →